G
Glyphic Biotechnologies
A biotechnology startup revolutionizing the field of proteomics
About Glyphic Biotechnologies
Glyphic Biotechnologies is a biotechnology startup revolutionizing the field of proteomics. The company is developing a first-of-its-kind, next-generation protein sequencing platform. This platform allows researchers to gain novel insights into biology and disease, providing a deeper understanding of what proteins reveal about bodily functions. Operating in the biotechnology market, Glyphic Biotechnologies primarily serves researchers and institutions focused on biological and medical research. The business model revolves around offering advanced sequencing services and potentially licensing its technology to other entities. Revenue is generated through service fees and technology licensing agreements.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Berkeley, United States
- Employees
- 33
- Open positions
- 6
- Dealroom signal
- 86.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Nov 2024 | $33M | $133M | LongeVC | ↗ |
| GRANTOther financing | Sep 2023 | $409K | — | National Institutes of Health | ↗ |
Growth signals
Latest recorded traffic for Glyphic Biotechnologies is 7.9K monthly website visits, down 1.2% over the last three months. Glyphic Biotechnologies's team grew 17.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Glyphic Biotechnologies in the Berkeley ecosystem
The Glyphic Biotechnologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed10 investors entered at this stage
OMX Ventures
Wing Venture Capital
Artis Ventures
Osage University Partners
Trevor Martin
Cantos Ventures
Civilization Ventures
Axial VC
National Institutes of Health
Johnson & Johnson Innovation
Series A1 investor entered at this stage
LongeVC
Other known investors10 additional known investors
Falling Walls Foundation
Massachusetts Institute of Technology
BioTools Innovator- BCBluebirds Capital
California Life Sciences
Calm Ventures
FoundersX Ventures
QB3
StartOut Growth Lab
StartX
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Glyphic Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Glyphic Biotechnologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









